WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg/m2 dose level have experienced tumor size reductions – of 18% and 20% respectively – after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction.
The Phase 1b clinical trial data is continuing to support Monopar’s dose-response hypothesis with camsirubicin. The best response seen prior to the current 650 mg/m2 dose level was at the immediately prior dose level (520 mg/m2), which was a 21% reduction in tumor size in a patient after receiving six cycles of camsirubicin treatment. This patient’s cancer was unresectable at study entry, but after the tumor size reduction, became eligible and the patient underwent successful surgical removal of their cancer with clear margins. Furthermore, all three patients at the 520 mg/m2 dose level achieved stable disease and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug.
Additionally, no drugrelated cardiotoxicity has been observed in the trial to date as evaluated by the industry standard left ventricular ejection fraction (LVEF), and no toxicities have been experienced by any patient that have required expanding the size of a dose cohort. Further, 71% of camsirubicin patients have experienced no hair loss, and only approximately 14% have experienced >50% hair loss, with the remainder having low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss. Only 14% of camsirubicin patients in the Phase 1b trial have experienced mild-to-severe oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin-treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis.
ASTS is a deadly cancer with inadequate treatment options. Doxorubicin is currently the first-line standard of care treatment for most types of ASTS, and the average life expectancy from time of diagnosis for these patients is only about 12 to 15 months. Because of the risk of irreversible heart damage, patients discontinue doxorubicin treatment after just 6 to 8 cycles. Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The value-driving hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes.
Camsirubicin Clinical Trial Design and GEIS Collaboration
The purpose of this dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD is reached, Monopar has a clinical collaboration agreement in place with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) to conduct a multi-country randomized Phase 2 clinical trial. The Phase 2 plan is to evaluate camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar.
Further information about this actively enrolling, open-label, dose-escalation Phase 1b clinical trial is available at www.ClinicalTrials.gov under study identifier NCT 05043649.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinicalstage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR101, a latestage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR202, an earlystage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that additional cycles of camsirubicin treatment may result in further tumor size reduction; that the hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes; and Monopar’s plans to conduct a multi-country randomized Phase 2 clinical trial once the MTD is reached evaluating camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar. The forward-looking statements involve risks and uncertainties including, but not limited to: the camsirubicin Phase 1b trial not proving safety and efficacy at higher doses; not successfully recruiting additional patients and initiating additional clinical trial sites for the camsirubicin Phase 1b clinical trial within expected timeframes, if at all; the Company’s inability to raise sufficient funds or engage a partner to continue the camsirubicin clinical program beyond the Phase 1b clinical trial; GEIS not conducting the camsirubicin Phase 2 clinical trial; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:??
Monopar Therapeutics Inc.
Investor Relations??
Kim R. Tsuchimoto??
Chief Financial Officer??
kimtsu@monopartx.com
Follow Monopar on social media for updates:?
Twitter: @MonoparTx? LinkedIn: Monopar Therapeutics
https://www.globenewswire.com/newsroom/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=
https://ml.globenewswire.com/media/Mjc5OTExN2QtZGQwZC00YTgxLTk3OGUtMzA0ZDk0MmY4YjU1LTEyMDU0MTY=/tiny/Monopar-Therapeutics-Inc-.png
Source: Monopar Therapeutics Inc.
© 2023 GlobeNewswire, Inc.
Recent MNPR News
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients • GlobeNewswire Inc. • 04/10/2024 12:00:22 PM
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:00:14 PM
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program • GlobeNewswire Inc. • 03/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 06:45:43 PM
- Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:59:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:22 PM
- Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:00:15 PM
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:39:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:36:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:00:13 PM
- Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 11:00:14 AM
- Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting • GlobeNewswire Inc. • 11/01/2023 11:00:00 AM
- Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference • GlobeNewswire Inc. • 10/10/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 11:37:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 11:30:33 PM
- Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 11:00:00 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM